PHAT Phathom Pharmaceuticals, Inc.

Nasdaq phathompharma.com


$ 12.48 $ -0.03 (-0.24 %)    

Tuesday, 14-Oct-2025 15:59:59 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 12.5
$ 12.17
$ 11.42 x 174
$ 12.50 x 10
$ 11.49 - $ 12.77
$ 2.21 - $ 19.50
1,638,801
na
886.8M
$ 1.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-07-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-02-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-30-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-12-2020 03-31-2020 10-Q
23 03-19-2020 12-31-2019 10-K
24 11-25-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 phathom-pharmaceuticals-appoints-sanjeev-narula-as-chief-financial-and-business-officer

Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor str...

 phathom-pharmaceuticals-sees-fy2025-sales-165000m-175000m-vs-159818m-est

Phathom Pharmaceuticals (NASDAQ:PHAT) sees FY2025 sales of $165.000 million-$175.000 million vs $159.818 million analyst estimate.

 phathom-pharmaceuticals-q2-adj-eps-079-beats-098-estimate-sales-39503m-beat-36383m-estimate

Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate ...

 craig-hallum-maintains-buy-on-phathom-pharmaceuticals-raises-price-target-to-17

Craig-Hallum analyst Chase Knickerbocker maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and raises the price tar...

 hc-wainwright--co-reiterates-buy-on-phathom-pharmaceuticals-maintains-20-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $...

 phathom-pharmaceuticals-stock-doubles-after-fda-grants-full-10-year-exclusivity-for-voquezna

Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) shares are trading lower Friday after the company announced a major regulatory win.

 needham-maintains-buy-on-phathom-pharmaceuticals-maintains-28-price-target

Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $28 price target.

 update-watching-phathom-pharmaceuticals-shares-spike-higher-fda-has-granted-the-co-the-10-year-nce-exclusivity-and-the-correction-to-the-orange-book-listings-for-10-mg--20-mg-voquezna-tablets-to-reflect-full-10-year-nce-exclusivity-through-may-3-2032

https://downloads.regulations.gov/FDA-2024-P-5703-0013/attachment_1.pdf

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION